TY - JOUR
T1 - Baseline factors prognostic of sustained virological response in patients with HIV-hepatitis C virus co-infection
AU - Dore, Gregory J.
AU - Torriani, Francesca J.
AU - Rodriguez-Torres, Maribel
AU - Bräu, Norber
AU - Sulkowski, Mark
AU - Lamoglia, Ricard Sola
AU - Tural, Cristina
AU - Clumeck, Nathan
AU - Nelson, Mark R.
AU - Mendes-Correa, Maria C.
AU - Godofsky, Eliot W.
AU - Dieterich, Douglas T.
AU - Yetzer, Ellen
AU - Lissen, Eduardo
AU - Cooper, David A.
PY - 2007/7
Y1 - 2007/7
N2 - OBJECTIVE: To identify baseline characteristics predictive of a sustained virological response (SVR) in patients with HIV-hepatitis C virus (HCV) co-infection treated with interferon-based therapy. DESIGN/METHODS: A stepwise multiple logistic regression analysis was used to explore the prognostic factors associated with SVR [undetectable HCV-RNA (< 50 IU/ml) at the end of untreated follow-up in week 72]. RESULTS: In all patients (n = 853), in addition to the HCV therapy received, the factors most predictive of SVR were baseline HCV-RNA [≤ versus > 400 000 IU/ml; odds ratio (OR) 4.77; 95% confidence interval (CI) 3.15-7.22; P < 0.0001] and HCV genotype (OR 2.87; 95% CI 2.00-4.12; P < 0.0001). HIV treatment (with a protease inhibitor or non-nucleoside reverse transcriptase inhibitor; P = 0.034), race (P = 0.027), and body mass index (P = 0.039) were also weak predictors of HCV treatment response. CONCLUSIONS: In the AIDS PEGASYS Ribavirin International Co-infection Trial (APRICOT), the predictors of SVR among HIV-HCV co-infected patients treated with peginterferon alfa-2a plus ribavirin were similar to those in patients with HCV mono-infection. The HCV genotype and pretreatment HCV-RNA level had the greatest influence on SVR.
AB - OBJECTIVE: To identify baseline characteristics predictive of a sustained virological response (SVR) in patients with HIV-hepatitis C virus (HCV) co-infection treated with interferon-based therapy. DESIGN/METHODS: A stepwise multiple logistic regression analysis was used to explore the prognostic factors associated with SVR [undetectable HCV-RNA (< 50 IU/ml) at the end of untreated follow-up in week 72]. RESULTS: In all patients (n = 853), in addition to the HCV therapy received, the factors most predictive of SVR were baseline HCV-RNA [≤ versus > 400 000 IU/ml; odds ratio (OR) 4.77; 95% confidence interval (CI) 3.15-7.22; P < 0.0001] and HCV genotype (OR 2.87; 95% CI 2.00-4.12; P < 0.0001). HIV treatment (with a protease inhibitor or non-nucleoside reverse transcriptase inhibitor; P = 0.034), race (P = 0.027), and body mass index (P = 0.039) were also weak predictors of HCV treatment response. CONCLUSIONS: In the AIDS PEGASYS Ribavirin International Co-infection Trial (APRICOT), the predictors of SVR among HIV-HCV co-infected patients treated with peginterferon alfa-2a plus ribavirin were similar to those in patients with HCV mono-infection. The HCV genotype and pretreatment HCV-RNA level had the greatest influence on SVR.
KW - APRICOT
KW - Co-infection
KW - Hepatitis C virus
KW - Sustained virological response
UR - http://www.scopus.com/inward/record.url?scp=34447557657&partnerID=8YFLogxK
U2 - 10.1097/QAD.0b013e328216f2c7
DO - 10.1097/QAD.0b013e328216f2c7
M3 - Article
C2 - 17630550
AN - SCOPUS:34447557657
SN - 0269-9370
VL - 21
SP - 1555
EP - 1559
JO - AIDS
JF - AIDS
IS - 12
ER -